Tapering Schedule for Discontinuing Bupropion XL 150 mg Once Daily
For a patient on bupropion XL 150 mg once daily for 3 years, the FDA-approved discontinuation protocol is straightforward: simply stop the 150 mg dose without further tapering, as this is already the lowest therapeutic dose of the XL formulation. 1
FDA-Approved Discontinuation Protocol
The FDA label explicitly states that when discontinuing bupropion XL 300 mg once daily, the dose should be decreased to 150 mg once daily prior to discontinuation—but provides no further tapering instructions for patients already on 150 mg daily. 1
Bupropion XL 150 mg represents the minimum therapeutic dose of the extended-release formulation; no lower-dose XL tablets exist, making further dose reduction within the same formulation impossible. 1
Why Switching to SR 75 mg Is Not Recommended
Bupropion SR and XL formulations are not interchangeable in their dosing schedules despite delivering comparable total daily exposure—the SR formulation requires twice-daily dosing with the second dose before 3 PM, creating a different pharmacokinetic profile. 2
No 75 mg SR formulation is FDA-approved or commercially available; the standard SR tablets are 100 mg, 150 mg, and 200 mg, making your proposed "SR 75 mg" regimen impossible to execute. 2
Switching formulations during discontinuation introduces unnecessary complexity and potential for dosing errors, particularly since the SR formulation's twice-daily schedule differs fundamentally from the XL once-daily regimen. 2
Evidence on Bupropion Discontinuation Symptoms
Withdrawal symptoms from bupropion discontinuation—including irritable mood, anxiety, sleeplessness, headache, and generalized aches—have been documented in case reports, though they appear less severe than with serotonergic antidepressants. 3
These discontinuation symptoms typically emerge within days of stopping the medication and should not be confused with relapse of the underlying anxiety or depressive disorder. 3, 4
A Cochrane review of antidepressant discontinuation found that most tapering regimens studied lasted four weeks or less, but noted that withdrawal symptoms are often confounded with relapse symptoms in the literature, making true incidence difficult to determine. 5
Practical Discontinuation Strategy for Your Patient
Option 1: Direct Discontinuation (FDA-Approved Method)
Week 1–2: Continue bupropion XL 150 mg once daily in the morning. 1
Week 3 onward: Stop bupropion XL 150 mg completely. 1
Monitor closely for withdrawal symptoms (anxiety, irritability, insomnia, headache, generalized aches) during weeks 3–5 after discontinuation. 3, 4
Option 2: Extended Taper Using Alternate-Day Dosing (Off-Label)
If you are concerned about withdrawal symptoms despite the FDA label not requiring further taper:
Week 1–2: Continue bupropion XL 150 mg once daily. 1
Week 3–4: Bupropion XL 150 mg every other day (Monday, Wednesday, Friday, Sunday pattern). (Extrapolated from general antidepressant tapering principles) 4, 6
Week 5–6: Bupropion XL 150 mg every third day (Monday, Thursday pattern). (Extrapolated from general antidepressant tapering principles) 4, 6
Important caveat: This extended taper is not FDA-approved and creates an unconventional dosing pattern that may produce fluctuating drug levels, potentially triggering more withdrawal symptoms than abrupt discontinuation. 1
Critical Monitoring During Discontinuation
Assess for neuropsychiatric symptoms weekly during the first month after discontinuation, including suicidal ideation, agitation, irritability, worsening anxiety, panic symptoms, and unusual behavioral changes. 2, 1
Distinguish withdrawal symptoms (anxiety, dizziness, headache, insomnia, irritability) from relapse of the underlying anxiety disorder—withdrawal symptoms typically peak within 1–2 weeks and resolve within 2–4 weeks, whereas relapse symptoms persist and worsen over time. 3, 4, 6
If significant withdrawal symptoms emerge, consider resuming bupropion XL 150 mg and attempting a slower taper using the alternate-day schedule described above. 4, 6
Why Bupropion May Have Been Suboptimal for This Patient
Bupropion is not FDA-approved for anxiety disorders and carries a debated risk of exacerbating anxiety symptoms, particularly at higher doses or in patients with prominent anxious features. 7
Clinical trials suggest bupropion may reduce anxiety symptoms in depressed patients with mild-to-moderate comorbid anxiety, but SSRIs or SNRIs are generally preferred for severe anxiety or primary anxiety disorders. 7
The activating properties of bupropion (due to norepinephrine and dopamine reuptake inhibition) can provoke or worsen anxiety in susceptible individuals, making it a less-than-ideal choice for anxiety disorder with SAD elements. 7
Post-Discontinuation Management
After successful discontinuation, continue monitoring for relapse of anxiety or depressive symptoms for at least 4–6 months, as this is the highest-risk period for recurrence. 8, 4
If anxiety symptoms re-emerge after discontinuation, consider evidence-based first-line treatments for anxiety disorders such as SSRIs (escitalopram, sertraline), SNRIs (venlafaxine, duloxetine), or cognitive-behavioral therapy rather than restarting bupropion. 8, 7
For seasonal affective disorder specifically, consider light therapy (10,000 lux for 30 minutes daily in the morning) as a non-pharmacologic alternative if symptoms recur seasonally. 1
Common Pitfalls to Avoid
Do not attempt to compound or split bupropion XL tablets to create lower doses—the extended-release mechanism is destroyed by crushing, dividing, or chewing, potentially causing dangerous peak drug levels and increased seizure risk. 1
Do not switch to bupropion SR during the taper unless you can ensure twice-daily dosing compliance with the second dose before 3 PM, as late-day SR dosing significantly increases insomnia risk. 2
Do not misinterpret early withdrawal symptoms (anxiety, irritability, insomnia) as immediate relapse requiring medication resumption—allow 2–4 weeks to distinguish transient withdrawal from true relapse. 3, 4, 6
Do not abruptly discontinue if the patient has been taking doses higher than prescribed or has been non-compliant with erratic dosing patterns, as this increases withdrawal symptom severity. 4